These genetic analyses (summarized in Table 1) serve as examples for how MR may inform all stages of drug development, including anticipation of results from ongoing clinical trials investigating inhibition of IL-6 signaling for the prevention of cardiovascular disease and preservation of kidney function (Ridker and Rane, 2021). This evidence concerns the gene IL6 and cardiovascular disorder.